Cardinal Health Inc.
 (CAH)

- NYSE
What's your position on ?
Bullish
Bearish
Why are you ish?
Skip
Post
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • Nov. 2, 2015, 9:14 AM
    | Nov. 2, 2015, 9:14 AM
  • Aug. 25, 2015, 12:58 PM
    • Cardinal Health (CAH +3.3%) agrees to acquire 71% of privately-held NaviHealth for ~$290M, with plans to acquire the rest of the business from founders and investors over the next four years.
    • Tennessee-based NaviHealth is a software and analytics company that helps health systems and insurers better manage the care of patients after discharge to keep them from returning to the hospital.
    • CAH expects the acquisition to be neutral to FY 2016 non-GAAP EPS from continuing operations since it is a partial period, and slightly accretive to results beginning in FY 2017, the first full year following the deal's close.
    | Aug. 25, 2015, 12:58 PM
  • Mar. 2, 2015, 8:55 AM
    • As rumored, Johnson & Johnson (NYSE:JNJ) sells its underperforming Cordis unit to Cardinal Health (NYSE:CAH), which picks up the interventional vascular technology business for $1.99B. The transaction is expected to close by end of the year.
    • Both stocks are unchanged premarket.
    • Previously: J & J rumored to have found a buyer for Cordis unit (Feb. 23)
    | Mar. 2, 2015, 8:55 AM
  • Jun. 13, 2013, 3:49 PM

    "Bargain hunters should be buying" shares of Cardinal Health (CAH +1.6%) Barron's Jack Hough says. Although contract losses (Express Scripts and Walgreen) will hit FY13 and FY14 revenues hard, CAH may actually see a benefit in terms of margin expansion. Additionally, the liquidation of inventory tied to Walgreen should bring in $500M in cash. Add this to the prospect of a return to double-digit earnings growth two years from now and things don't look half bad.

    | Jun. 13, 2013, 3:49 PM
  • May 2, 2013, 10:48 AM

    Cardinal Health (CAH +4.7%) moves up today after FQ3 results beat on a per share basis. Net earnings rose 3.6% Y/Y, boosted by a tax benefit and stronger margins. Gross margin rose to 5.3% from 4.5%, as medical segment sales improved 3% and profit from the unit grew 12%. Its pharmaceutical segment reported a 10% decline in revenue, mostly on the non-renewal of its contract with Express Scripts and brand-to-generic conversions, but the unit's net profit still climbed 12%. The company also raises its FY13 EPS estimate to between $3.67 and $3.71, versus previous estimates of $3.42 to $3.50.

    | May 2, 2013, 10:48 AM
  • Mar. 19, 2013, 10:06 AM

    AmerisourceBergen's distribution deal with Walgreen means that the latter's contract with Cardinal Health (CAH -7%) will end in August. Cardinal tries to put a brave face on things, saying it's targeting EPS from continuing ops at least similar to FY 2013's projected $3.42-3.50. And while Walgreen accounted for 21% of Cardinal's revenue in FY 2012, the non-renewal will lead to a "meaningful" net benefit to cash flow in FY 2014. (PR)

    | Mar. 19, 2013, 10:06 AM
  • Mar. 19, 2013, 9:10 AM
    Premarket gainers: NPSP +10%. SKUL +7%. ABC +6%. ACAD +5%.
    Losers: AFFY -59%. HNR -46%. MTSL -30%. STSI -11%. CAH -8%. DSW -7%. HPT -6%.
    | Mar. 19, 2013, 9:10 AM
  • Mar. 19, 2013, 8:41 AM

    CardinalHealth (CAH) tumbles 5.2% after AmerisourceBergen (ABC) signs a 10-year distribution deal with Walgreen and its partner Alliance Boots. Meanwhile, CardinalHealth has completed its $2.07B acquisition of privately held AssuraMed, a provider of medical supplies to patients in the home.

    | Mar. 19, 2013, 8:41 AM
  • Feb. 14, 2013, 8:08 AM

    Cardinal Health (CAH) agrees to acquire closely-held direct-to-home medical supplies provider AssuraMed for $2.07B. The deal will be financed with $1.3B in new senior unsecured notes and cash. CAH says the deal would add $0.02-$0.03/share to FY 2013 adjusted earnings if the deal closes in early April, and at least $0.18/share in FY 2014. CAH +1.2% premarket.

    | Feb. 14, 2013, 8:08 AM
  • Feb. 5, 2013, 1:40 PM

    Cardinal Health (CAH +1.6%) puts up a decent FQ2 report this morning, despite weaker revenue out of its pharmaceutical unit, due in part to brand-to-generic conversions and the loss of the Express Scripts business. Net earnings still managed to rise by 16% Y/Y however, as the drug wholesaler posted better margins. Revenue in its pharmaceutical business its largest by revenue, declined 8%, while its medical business increased by 3%, boosted by last year's acquisition of FutureMed and an additional sales day.

    | Feb. 5, 2013, 1:40 PM
  • Sep. 5, 2012, 12:38 PM
    Cardinal Health (CAH -1.5%) slides after being downgraded to Market Perform at William Blair earlier today. The firm says there's some uncertainty regarding contract renewals with Walgreens, who appears to be considering moving its brand purchasing in-house.
    | Sep. 5, 2012, 12:38 PM
  • Oct. 7, 2011, 3:22 PM
    Cardinal Health (CAH +0.8%)) gains after Susquehanna ups the shares to postive from neutral on valuation, saying the company should benefit from upcoming launches of some of its generic drugs.
    | Oct. 7, 2011, 3:22 PM
Company Description
Cardinal Health Inc is a healthcare services company. It provides pharmaceutical & medical products & services that help pharmacies, hospitals and other healthcare providers focus on patient care. It also provides medical products to patients in the home.
Sector: Services
Industry: Drugs Wholesale
Country: United States